Supplemental Information

Cube-octameric silsesquioxane-mediated cargo peptide delivery into living cancer cells

Sebastian Hörner, Sebastian Fabritz, Henry D. Herce, Olga Avrutina, Christian Dietz, Robert W. 5 Stark, M. Cristina Cardoso, and Harald Kolmar

Content

10

Compound 2 (Fmoc-L-cysteine heptaamino-COSS) and 2a (Fmoc-(S-trityl)-L-cysteine heptaamino-COSS)

Fig. S1: Chemical structure of trityl protected (2a) and unprotected Fmoc-L-cysteine heptaamino-COSS 2

Fig. S2: Analytical RP-HPLC traces of trityl protected (2a) and unprotected Fmoc-L-cysteine heptaamino-COSS 2

Fig. S3: HR-MS measurement of compound 2a

Fig. S4: LC-MS (ESI) measurement of compound 2

15 Compound 3 (fluorescein-labeled PCNA binding peptide)

Fig. S5: Amino acid sequence and chemical structure of fluorescein-labeled PCNA binding peptide 3

Fig. S6: Analytical HPLC traces of fluorescein-labeled PCNA binding peptide 3

Fig. S7: LC-MS (ESI) measurements of the purified and fluorescein-labeled PCNA binding peptide 3

20 Compound 4 (PCNA binding peptide coupled to Fmoc-L-cysteine heptaamino-COSS)

Fig. S8: Chemical structure of compound 4

Fig. S9: Analytical RP-HPLC traces of compound 4

Fig. S10: HR-MS measurement of a compound 4

Fig. S11: FT-IR spectrum of compound 4

25

Compound 5 (L-cysteine-β-alanine-fluorescein hepataamino-COSS), 5a (L-cysteine-(S-trityl)-β-alanine-fluorescein), and 5b (L-cysteine-(S-trityl)-β-alanine-fluorescein hepataamino-COSS)

Fig. S12: Chemical structure of compound 5a

- Fig. S13: Analytical RP-HPLC traces of compound 5a
- Fig. S14: LC-MS (ESI) measurement of compound 5a
- Fig. S15: Chemical structure of trityl-protected (5b) and unprotected L-cysteine-β-alanine-fluorescein hepataamino-COSS 5
- Fig. S16: LC-MS (ESI) measurement of L-cysteine-(S-trityl)-β-alanine-fluorescein heptaamino-COSS 5b

Fig. S17: Analytical RP-HPLC traces and MS analysis of L-cysteine-(S-trityl)-β-alanine-fluorescein hepataamino-COSS 5

35

30

Microirradiation experiment and subsequent co-localization of fluorescently labeled PCNA-binding peptide and RFP-labeled PCNA after the addition of compound 4

Fig. S18: Fluorescence microscopic analysis of irradiated HeLa cells

40

45

55



Compound 2 (Fmoc-L-cysteine heptaamino-COSS) and 2a (Fmoc-(S-trityl)-L-cysteine heptaamino-⁵ COSS)



Fig. S1: Chemical structure of Fmoc-(S-trityl)-L-cysteine heptaamino-COSS 2a (left) and unprotected Fmoc-L-cysteine heptaamino-COSS 2 (right).



Fig. S2: Analytical RP-HPLC traces of trityl-protected (**2a**) and deprotected Fmoc-L-cysteine heptaamino-COSS **2**. (*Varian* 940-³⁵ LC equipped with a *Phenomenex* Luna C₁₈ column (5u, 100 A, 250×4.60 mm, 5 µm). Eluent A: 0.1% aq. trifluoroacetic acid (TFA), eluent B: 90 % aq. acetonitrile in 0.1% aq. TFA; 10 \rightarrow 80% B in 20 min preceded by 5 min isocratic 10 % B at a flow rate of 1 mL min⁻¹).



Fig. S3: HR-MS measurement of compound **2a**; left: calculated isotopic pattern $[M+2H]^{2+} = 724.7406$; right: measured isotopic pattern $[M+2H]^{2+} = 724.7409$.





5

Compound 3 (fluorescein-labeled PCNA binding peptide)



Chemical Formula: C₁₁₆H₁₆₄N₂₆O₃₀S₂ Exact Mass: 2465,15 Molecular Weight: 2466,83

Fig. S5: Amino acid sequence and chemical structure of fluorescein-labeled PCNA binding peptide 3.



Fig. S6: Analytical RP-HPLC traces of FITC-labeled PCNA binding peptide **3** (*Varian* 940-LC equipped with a *Phenomenex* Luna C₁₈ column (5u, 100 A, 250×4.60 mm, 5 μ m). Eluent A: 0.1% aq. trifluoroacetic acid (TFA), eluent B: 90 % aq. acetonitrile in 0.1% aq. ¹⁰ TFA; 25 \rightarrow 50% B in 20 min preceded by 5 min isocratic 25 % B at a flow rate of 1 mL min⁻¹).

25

20

15



Fig. S7: LC-MS (ESI) measurement of the purified fluorescein-labeled PCNA binding peptide 3.

10

Compound 4 (fluorescently labeled PCNA binding peptide coupled to Fmoc-L-cysteine heptaamino-COSS)



Fig. S8: Chemical structure of compound 4.



10

15

Fig. S9: Analytical RP-HPLC traces of compound 4 (*Varian* 940-LC equipped with a *Phenomenex* Luna C₁₈ column (5u, 100 A, 250×4.60 mm, 5 µm). Eluent A: 0.1% aq. trifluoroacetic acid (TFA), eluent B: 90 % aq. acetonitrile in 0.1% aq. TFA; 25 \rightarrow 50% B in 20 min preceded by 5 min isocratic 10 % B at a flow rate of 1 mL min⁻¹).



Fig. S10: HR-MS measurement of compound **4**; left: calculated isotopic pattern $[M+5H]^{5+}=734.7065$; right: measured isotopic pattern $[M+5H]^{5+}=734.7077$.



Fig. S11: FT-IR spectrum of compound 4.

15

10

5

 $Compound \ 5 \ (cysteine-\beta-alanine-fluorescein \ hepataamino-COSS), \ 5a \ (cysteine-(S-trityl)-\beta-alanine-fluorescein), \ and \ 5b \ (cysteine-(S-trityl)-\beta-alanine-fluorescein \ hepataamino-COSS)$



Fig. S12: Chemical structure of compound 5a.



Fig. S13: Analytical RP-HPLC traces of compound **5a**. (*Varian* 940-LC equipped with a *Phenomenex* Luna C₁₈ column (5u, 100 A, 250×4.60 mm, 5 μ m). Eluent A: 0.1% aq. trifluoroacetic acid (TFA), eluent B: 90 % aq. acetonitrile in 0.1% aq. TFA; 10 \rightarrow 100% B in 20 min preceded by 5 min isocratic 10 % B at a flow rate of 1 mL min⁻¹).

<Chromatogram>



Fig. S14: LC-MS (ESI) measurement of compound 5a.

10

Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012



Fig. S15: Chemical structures of trityl protected 5b (left) and unprotected cysteine- β -alanine-fluorescein hepataamino-COSS 5 (right).



Fig. S16: LC-MS (ESI) measurement of cysteine-(S-trityl)-β-alanine-fluorescein hepataamino-COSS 5b.



Fig. S17: Analytical RP-HPLC traces (*Varian* 940-LC equipped with a *Phenomenex* Luna C₁₈ column (5u, 100 A, 250×4.60 mm, 5 μ m). Eluent A: 0.1% aq. trifluoroacetic acid (TFA), eluent B: 90 % aq. acetonitrile in 0.1% aq. TFA; 10 \rightarrow 100% B in 20 min preceded by 5 min isocratic 10 % B at a flow rate of 1 mL min⁻¹) and MS analysis of cysteine- β -alanine-fluorescein hepataamino-COSS **5**.

Microirradiation experiment and subsequent co-localization of fluorescently labeled PCNA binding peptide and RFP labeled PCNA after the addition of compound 4



Fig. S18: Fluorescence microscopic analysis of irradiated HeLa cells 30 minutes after the addition of compound **4**. (a) PCNA (red); (b) cleaved fluorescein-labeled peptide **3** (green); (c) contrast image ; (d) overlay.